Forvisirvat

Sirtuin-6 activator From Wikipedia, the free encyclopedia

Forvisirvat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name SP-624) is a sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia.[1][2][3][4][5] It is taken by mouth.[1] As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia.[1][2][4] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.[1][2][5]

Other namesSP624
Routes of
administrationOral[1]
Drug classSirtuin-6 (SIRT6) activator[1]
CAS Number
Quick facts Clinical data, Other names ...
Forvisirvat
Clinical data
Other namesSP624
Routes of
administration		Oral[1]
Drug classSirtuin-6 (SIRT6) activator[1]
Identifiers
  • (2S,5'R)-7-chloro-3',4-dimethoxy-5'-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC19H17ClN2O6
Molar mass404.80 g·mol−1
3D model (JSmol)
  • C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(C=C(C(=C3O2)Cl)C4=NN=C(O4)C)OC)OC
  • InChI=1S/C19H17ClN2O6/c1-8-5-10(23)6-13(26-4)19(8)17(24)14-12(25-3)7-11(15(20)16(14)28-19)18-22-21-9(2)27-18/h6-8H,5H2,1-4H3/t8-,19+/m1/s1
  • Key:MIHSWFYCAJWPIS-YLVJLNSGSA-N
Close

See also

References

Related Articles

Wikiwand AI